Zanubrutinib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-ZANUBRUTINIB |
|---|---|
| Type | Drug |
| Aliases | BrukinsaЗанубрутиніб |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-CLL DIS-WM |
| Sources | SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | Second-generation BTK inhibitor (highly selective) |
|---|---|
| Mechanism | Covalent irreversible BTK inhibitor with optimized selectivity vs ibrutinib — minimal off-target binding to TEC/ITK/EGFR, lower cardiac toxicity, lower bleeding. |
| Typical dosing | 160 mg PO BID OR 320 mg PO once daily, continuous until progression or intolerance |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Approved for CLL, MCL, WM, MZL r/r. ASPEN trial in WM: superior hematologic response + safety vs ibrutinib in MYD88-mutated cohort. Ukraine: registered, NOT НСЗУ-reimbursed.
Used By
Regimens
REG-ZANUBRUTINIB-CONTINUOUS- Zanubrutinib monotherapy (continuous, ALPINE-style)REG-ZANUBRUTINIB-WM- Zanubrutinib monotherapy (continuous)REG-ZANUBRUTINIB-WM-RELAPSED- Zanubrutinib monotherapy continuous for r/r WM (ASPEN schedule) — alternative to ibrutinib